1:45 PM (PT)
-
A longstanding priority for both Congress and FDA, there has been a significant evolution in recent years in the ways in which patients’ experiences and preferences have been incorporated into the dru ...Breakout Session
-
Orphan and Rare Disease
-
-
Real world data (RWD) are increasingly relied upon to inform drug policy decisions at both the state and federal levels. For example, state Prescription Drug Affordability Boards (PDABs) are using all ...Breakout Session
-
Value, Patient Access and Reimbursement
-
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
3:00 PM (PT)
-
Biomarker legislation is reshaping insurance and diagnostics policy across many US states, with more than 20 currently mandating coverage for biomarker testing under certain conditions. However, trans ...Breakout Session
- Value, Patient Access and Reimbursement
-
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
4:15 PM (PT)
-
There’s no question that drug development is a risky endeavor with scientific, clinical, and commercial risk. Patients and society value advances in science that help people get well, stay healthy, an ...Breakout Session
- Value, Patient Access and Reimbursement
-
)
)
11:00 AM (PT)
-
Healthcare providers are often faced with the same set of challenges when diagnosing women with Alzheimer’s – debunking the stigma that has shaped the Alzheimer’s narrative for women and their familie ...Breakout Session
-
Patient Advocacy
-
)
)
)
1:45 PM (PT)
-
Clinical trials in small populations, particularly those with progressive or degenerative rare diseases, face scientific and ethical hurdles that challenge traditional trial frameworks. High phenotypi ...Breakout Session
- Orphan and Rare Disease
-
-
Nearly a year ago, the One Big Beautiful Bill became law and states immediately felt the implications of its sweeping health care provisions. This session will provide a cross-stakeholder view on how ...Breakout Session
- Value, Patient Access and Reimbursement
-
-
Super SessionAdvances in biotechnology are rewriting medicine and redefining the patient experience. At the forefront of each scientific breakthrough are the patients who made it possible. This session celebrates ...Super Session
- Patient Advocacy
-
)
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
2:55 PM (PT)
-
Infixion Bioscience is developing first in class, FDA bound treatments for Neurofibromatosis Type 1 (NF1), a genetic disease affecting 125,000 people in the U.S. and 2.5M worldwide. Founded by NF1 par ...Start-Up Stadium Session
- Orphan and Rare Disease
-
3:10 PM (PT)
-
Super SessionSuperhuman Body: World of Medical Marvels, narrated by Matthew McConaughey, takes audiences inside the remarkable capabilities of the human body and the breakthroughs in science and bioengineering tha ...Super Session
- Patient Advocacy
-
4:15 PM (PT)
-
Congress created the Rare Pediatric Disease Priority Review Voucher (PRV) program to incentivize the development of drugs for serious or life-threatening rare diseases in children. Vouchers are earned ...Breakout Session
- Orphan and Rare Disease
-
-
We are living in a golden age of biopharmaceutical innovation. Yet, too often, patients face barriers between them and the appropriate treatment they need across various cost-shifting programs. Payers ...Breakout Session
- Patient Advocacy
-
-
The landmark ORPHAN Cures Act has catalyzed investment in rare disease research since its passage last year, bringing hope to millions of patients and their families. Early data demonstrates renewed p ...Breakout Session
- Orphan and Rare Disease
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
3:00 PM (PT)
-
The 340B program was initially intended to help safety net hospitals further serve vulnerable communities. However, the program has now ballooned into a massive profit generator for hospitals that oft ...Breakout Session
- Patient Advocacy
-
)
)
4:15 PM (PT)
-
Venture capital funding specifically for women’s health biotech and pharmaceuticals has undergone a significant transformation since 2023. While the broader "Women's Health" category is often dominate ...Breakout Session
- Patient Advocacy
-
)
)
)
9:00 AM (PT)
-
Colorado offers a collaborative environment for life sciences where companies, researchers, and partners work together, accelerating discoveries that save and change patient lives. In this interactive ...Breakout Session
- Patient Advocacy
-
-
Even though orphan drugs currently account for almost 50% of all new medicine approved in USA and EU, many conditions still lack therapeutic options, and it has been estimated that 90-95% of the more ...Breakout Session
- Orphan and Rare Disease
-
)
)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}